Early therapeutic intervention in females with Fabry disease?

Acta Paediatrica, International Journal of Paediatrics

Volumn 97, Issue SUPPL. 457, 2008, Pages 41-47

  Hughes, Derralynn A ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Galactosidase A; Early therapy; Enzyme replacement therapy; Fabry disease; Females; Heterozygotes

Indexed keywords

ALPHA GALACTOSIDASE; GLOBOTRIAOSYLCERAMIDE;

BIOCHEMISTRY; CONFERENCE PAPER; EARLY INTERVENTION; ENZYME REPLACEMENT; FABRY DISEASE; FEMALE; HISTOLOGY; HUMAN; KIDNEY FUNCTION; OBSERVATIONAL STUDY; PRIORITY JOURNAL; QUALITY OF LIFE; SEX DIFFERENCE; SURVIVAL;

AGE FACTORS; ALPHA-GALACTOSIDASE; CARDIOMYOPATHIES; CARDIOVASCULAR DISEASES; DISEASE PROGRESSION; FABRY DISEASE; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; ISOENZYMES; TRIHEXOSYLCERAMIDES;

EID: 41049102218     PISSN: 08035253     EISSN: 16512227     Source Type: Journal    
DOI: 10.1111/j.1651-2227.2008.00649.x     Document Type: Conference Paper

References (54)

1. Kint JA. Fabry's disease: α-galactosidase deficiency. Science 1970 167 : 1268 9.
2. Mehta A, Ricci R, Widmer U, Dehout F, Garcia de Lorenzo A, Kampmann C, et al. Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey. Eur J Clin Invest 2004 34 : 236 42.
3. MacDermot KD, Holmes A, Miners AH. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males. J Med Genet 2001 38 : 750 60.
4. MacDermot KD, Holmes A, Miners AH. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females. J Med Genet 2001 38 : 769 75.
5. Eng CM, Banikazemi M, Gordon RE, Goldman M, Phelps R, Kim L, et al. A phase 1/2 clinical trial of enzyme replacement in Fabry disease: pharmacokinetic, substrate clearance, and safety studies. Am J Hum Genet 2001 68 : 711 22.
6. Schiffmann R, Kopp JB, Austin HA 3rd., Sabnis S, Moore DF, Weibel T, et al. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA 2001 285 : 2743 9.
7. Moore DF, Altarescu G, Herscovitch P, Schiffmann R. Enzyme replacement reverses abnormal cerebrovascular responses in Fabry disease. BMC Neurol 2002 2 : 4 13.
8. Schiffmann R, Floeter MK, Dambrosia JM, Gupta S, Moore DF, Sharabi Y, et al. Enzyme replacement therapy improves peripheral nerve and sweat function in Fabry disease. Muscle Nerve 2003 28 : 703 10.
9. Hoffmann B, Reinhardt D, Koletzko B. Effect of enzymereplacement therapy on gastrointestinal symptoms in Fabry disease. Eur J Gastroenterol Hepatol 2004 16 : 1067 9.
10. Hoffmann B, Garcia de Lorenzo A, Mehta A, Beck M, Widmer U, Ricci R. Effects of enzyme replacement therapy on pain and health related quality of life in patients with Fabry disease: data from FOS (Fabry Outcome Survey). J Med Genet 2005 42 : 247 52.
11. Hajioff D, Goodwin S, Quiney R, Zuckerman J, MacDermot KD, Mehta A. Hearing improvement in patients with Fabry disease treated with agalsidase alfa. Acta Paediatr 2003 92 (Suppl 443 28 30.
12. Beck M, Ricci R, Widmer U, Dehout F, Garcia de Lorenzo A, Kampmann C, et al. Fabry disease: overall effects of agalsidase alfa treatment. Eur J Clin Invest 2004 34 : 838 44.
13. Banikazemi M, Ullman T, Desnick RJ. Gastrointestinal manifestations of Fabry disease: clinical response to enzyme replacement therapy. Mol Genet Metab 2005 85 : 255 9.
14. Banikazemi M, Bultas J, Waldek S, Wilcox WR, Whitley CB, McDonald M, et al. Agalsidase-beta therapy for advanced Fabry disease: a randomized trial. Ann Intern Med 2007 146 : 77 86.
15. Dehout F, Roland D, Treille de Granseigne S, Guillaume B, Van Maldergem L. Relief of gastrointestinal symptoms under enzyme replacement therapy in patients with Fabry disease. J Inherit Metab Dis 2004 27 : 499 505.
16. Vedder AC, Linthorst GE, Houge G, Groener JE, Ormel EE, Bouma BJ, et al. Treatment of Fabry disease: outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2 mg/kg. PLoS ONE 2007 2 : e598.
17. Ramaswami U, Wendt S, Pintos-Morell G, Parini R, Whybra C, Leon Leal JA, et al. Enzyme replacement therapy with agalsidase alfa in children with Fabry disease. Acta Paediatr 2007 96 : 122 7.
18. Ries M, Clarke JT, Whybra C, Timmons M, Robinson C, Schlaggar BL, et al. Enzyme-replacement therapy with agalsidase alfa in children with Fabry disease. Pediatrics 2006 118 : 924 32.
19. Deegan P, Baehner AF, Barba-Romero MA, Hughes D, Kampmann C, Beck M. Natural history of Fabry disease in females in the Fabry Outcome Survey. J Med Genet 2006 43 : 347 52.
20. Whybra C, Kampmann C, Willers I, Davies J, Winchester B, Kriegsmann J, et al. Anderson-Fabry disease: clinical manifestations of disease in female heterozygotes. J Inherit Metab Dis 2001 24 : 715 24.
21. Data on File 39.393 Shire HGT, Danderyd, Sweden.
22. National Institute for Health and Clinical Excellence. Appraising orphan drugs. Available from : http://www.nice.org.uk/niceMedia/pdf/smt/120705item4. pdf.
23. Lyon MF. Gene action in the X-chromosome of the mouse Mus musculus L. Nature 1961 190 : 372 3.
24. Lyon MF. X-chromosome inactivation and human genetic disease. Acta Paediatr 2002 91 (Suppl 439 107 12.
25. Happle R. X-chromosome inactivation: role in skin disease expression. Acta Paediatr 2006 95 (Suppl 451 16 23.
26. Dobyns WB. The pattern of inheritance of X-linked traits is not dominant or recessive, just X-linked. Acta Paediatr 2006 95 (Suppl 451 11 15.
27. Ashton-Prolla P, Ashley GA, Giugliani R, Pires RF, Desnick RJ, Eng CM. Fabry disease: comparison of enzymatic, linkage, and mutation analysis for carrier detection in a family with a novel mutation (30delG). Am J Med Genet 1999 84 : 420 4.
28. Desnick RJ, Bernstein HS, Astrin KH, Bishop DF. Fabry disease: molecular diagnosis of hemizygotes and heterozygotes. Enzyme 1987 38 : 54 64.
29. Desnick RJ, Ioannou YA, Eng CM. α-Galactosidase A deficiency: Fabry disease. In : Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The metabolic and molecular bases of inherited disease. 8th ed. New York : McGraw-Hill, 2001 : 3733 74.
30. Maier EM, Osterrieder S, Whybra C, Ries M, Gal A, Beck M, et al. Disease manifestations and X inactivation in heterozygous females with Fabry disease. Acta Paediatr 2006 95 (Suppl 451 30 8.
31. Mills K, Morris P, Lee P, Vellodi A, Waldek S, Young E, et al. Measurement of urinary CDH and CTH by tandem mass spectrometry in patients hemizygous and heterozygous for Fabry disease. J Inherit Metab Dis 2005 28 : 35 48.
32. Young E, Mills K, Morris P, Vellodi A, Lee P, Waldek S, et al. Is globotriaosylceramide a useful biomarker in Fabry disease? Acta Paediatr 2005 94 (Suppl 447 51 4.
33. Cable WJ, McCluer RH, Kolodny EH, Ullman MD. Fabry disease: detection of heterozygotes by examination of glycolipids in urinary sediment. Neurology 1982 32 : 1139 45.
34. Gupta S, Ries M, Kotsopoulos S, Schiffmann R. The relationship of vascular glycolipid storage to clinical manifestations of Fabry disease: a cross-sectional study of a large cohort of clinically affected heterozygous women. Medicine (Baltimore) 2005 84 : 261 8.
35. Chimenti C, Pieroni M, Morgante E, Antuzzi D, Russo A, Russo MA, et al. Prevalence of Fabry disease in female patients with late-onset hypertrophic cardiomyopathy. Circulation 2004 110 : 1047 53.
36. Hulkova H, Ledvinova J, Poupetova H, Bultas J, Zeman J, Elleder M. Postmortem diagnosis of Fabry disease in a female heterozygote leading to the detection of undiagnosed manifest disease in the family. Cas Lek Cesk 1999 138 : 660 4.
37. Osunkoya AO, Agte SD, Laszik Z. A 67-year-old woman with chronic proteinuria. Focal segmental and global glomerulosclerosis with light microscopic and ultrastructural features consistent with Fabry disease. Arch Pathol Lab Med 2006 130 : e93 5.
38. Sessa A, Meroni M, Battini G, Righetti M, Nebuloni M, Tosoni A, et al. Evolution of renal pathology in Fabry disease. Acta Paediatr 2003 92 (Suppl 443 6 8.
39. Giacomini PS, Shannon PT, Clarke JT, Jaigobin C. Fabry's disease presenting as stroke in a young female. Can J Neurol Sci 2004 31 : 112 14.
40. Rolfs A, Bottcher T, Zschiesche M, Morris P, Winchester B, Bauer P, et al. Prevalence of Fabry disease in patients with cryptogenic stroke: a prospective study. Lancet 2005 366 : 1794 6.
41. Deegan P, Baehner AF, Barba-Romero MA, Hughes D, Beck M. Fabry disease in females: clinical characteristics and the effects of enzyme replacement therapy. In : Mehta A, Beck M, Sunder-Plassmann G, editors. Fabry disease: perspectives from 5 years of FOS. Oxford : Oxford PharmaGenesis, 2006 : 295 304.
42. Baehner F, Kampmann C, Whybra C, Miebach E, Wiethoff CM, Beck M. Enzyme replacement therapy in heterozygous females with Fabry disease: results of a phase IIIB study. J Inherit Metab Dis 2003 26 : 617 27.
43. Whybra C, Kampmann C, Krummenauer F, Ries M, Mengel E, Miebach E, et al. The Mainz Severity Score Index: a new instrument for quantifying the Anderson-Fabry disease phenotype, and the response of patients to enzyme replacement therapy. Clin Genet 2004 65 : 299 307.
44. Data on File 39.324: Shire HGT, Danderyd, Sweden.
45. Ries M, Ramaswami U, Parini R, Lindblad B, Whybra C, Willers I, et al. The early clinical phenotype of Fabry disease: a study on 35 European children and adolescents. Eur J Pediatr 2003 162 : 767 72.
46. Cable WJ, Dvorak AM, Osage JE, Kolodny EH. Fabry disease: significance of ultrastructural localization of lipid inclusions in dermal nerves. Neurology 1982 32 : 347 53.
47. Lao LM, Kumakiri M, Mima H, Kuwahara H, Ishida H, Ishiguro K, et al. The ultrastructural characteristics of eccrine sweat glands in a Fabry disease patient with hypohidrosis. J Dermatol Sci 1998 18 : 109 17.
48. O'Brien BD, Shnitka TK, McDougall R, Walker K, Costopoulos L, Lentle B, et al. Pathophysiologic and ultrastructural basis for intestinal symptoms in Fabry's disease. Gastroenterology 1982 82 : 957 62.
49. Hughes DA, Ramaswami U, Elliott P, Deegan P, Lee P, Waldek S, et al. Guidelines for the diagnosis and management of Anderson-Fabry disease. Publications and statistics. Department of Health 2005 : 1 37.
50. Connock M, Juarez-Garcia A, Frew E, Mans A, Dretzke J, Fry-Smith A, et al. A systematic review of the clinical effectiveness and cost-effectiveness of enzyme replacement therapies for Fabry's disease and mucopolysaccharidosis type 1. Health Technol Assess 2006 10 : iii 136.
51. Gold KF, Pastores GM, Botteman MF, Yeh JM, Sweeney S, Aliski W, et al. Quality of life of patients with Fabry disease. Qual Life Res 2002 11 : 317 27.
52. Miners AH, Holmes A, Sherr L, Jenkinson C, MacDermot KD. Assessment of health-related quality-of-life in males with Anderson-Fabry disease before therapeutic intervention. Qual Life Res 2002 11 : 127 33.
53. Street NJ, Yi MS, Bailey LA, Hopkin RJ. Comparison of health-related quality of life between heterozygous women with Fabry disease, a healthy control population, and patients with other chronic disease. Genet Med 2006 8 : 346 53.
54. Moore DF, Ries M, Forget EL, Schiffmann R. Enzyme replacement therapy in orphan and ultra-orphan diseases: the limitations of standard economic metrics as exemplified by Fabry-Anderson disease. Pharmacoeconomics 2007 25 : 201 8.